文献速递胸部肿瘤

晚期非小细胞肺癌患者帕博利珠单抗剂量从200毫克每3周转换为400毫克每6周的安全性影响

Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2022-07-03

本研究纳入45例晚期非小细胞肺癌患者,在本研究所于2020年8月至2021年11月期间将帕博利珠单抗剂量从200毫克每3周转换为400毫克每6周。转换后三个周期内,17例(37.8%)患者出现新发或加重的免疫相关不良事件,其中肺炎11例(24.4%)。结论认为转换剂量后早期周期可出现新发或加重的免疫相关不良事件,尤其是肺炎,即使既往200毫克每3周治疗稳定的患者亦然。

要点

  • 45例晚期NSCLC患者帕博利珠单抗剂量从200毫克每3周转换为400毫克每6周。
  • 转换后三个周期内17例(37.8%)出现新发或加重的免疫相关不良事件。
  • 最常见为新发或加重的肺炎,共11例(24.4%)。

核心结论

  • 帕博利珠单抗剂量从200毫克每3周转换为400毫克每6周后,早期周期可出现新发或加重的免疫相关不良事件,尤其是肺炎,即使既往200毫克每3周治疗稳定的患者亦然。

研究设计与样本

  • 本研究纳入45例晚期非小细胞肺癌患者,在本研究所于2020年8月至2021年11月期间将帕博利珠单抗剂量从200毫克每3周转换为400毫克每6周。

主要发现

  • 转换时患者中位年龄为71岁(范围:32-84岁),男性32例(71.1%)。
  • 转换前200毫克每3周的中位周期数为6个(范围:1-31)。
  • 转换后三个周期内,45例患者中17例(37.8%)出现新发或加重的免疫相关不良事件。
  • 免疫相关不良事件包括肺炎11例(24.4%)、腹泻3例(6.7%)、肾功能不全2例(4.4%)、肾上腺功能不全2例(4.4%)、皮疹1例(2.2%)、暴发性1型糖尿病1例(2.2%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Administration of 400 mg pembrolizumab every 6 weeks (400 mg Q6W) has been approved on the basis of the results of simulated pharmacokinetic modeling and exposure-response analyses. Nevertheless, the safety of switching dosage from 200 mg every 3 weeks (Q3W) to 400 mg Q6W during treatment remains unclear. METHODS: This study involved patients (N = 45) with advanced NSCLC, in whom the pembrolizumab dosage was switched from 200 mg Q3W to 400 mg Q6W between August 2020 and November 2021 in our institute. RESULTS: At the time of switching, the median age of the patients was 71 (range: 32-84) years, and 32 patients (71.1 %) were males. The median number of cycles of 200 mg Q3W before switching was six (range: 1-31). After switching, new or worsening immune-related adverse events (irAEs) occurred in 17 of the 45 patients (37.8%) within three cycles. The irAEs were pneumonitis in 11 patients (24.4%), diarrhea in three patients (6.7%), renal dysfunction in two patients (4.4%), adrenal dysfunction in two patients (4.4%), a skin rash in one patient (2.2%), fulminant type 1 diabetes mellitus in one patient (2.2%). CONCLUSIONS: The switching of pembrolizumab dosage from 200 mg Q3W to 400 mg Q6W resulted in the occurrence of new or worsening irAEs, in particular, pneumonitis, in the early cycles even in patients who had received stable treatment with 200 mg Q3W.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Higashiyama RI, Yoshida T, Yagishita S, et al. Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC. J Thorac Oncol. 2022. PMID: 35788404. doi:10.1016/j.jtho.2022.06.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。